Discovering The Potential of AXIN1 as A Drug Target Or Biomarker

Target Name: AXIN1

NCBI ID: G8312

AXIN1

Discovering The Potential of AXIN1 as A Drug Target Or Biomarker

Axis inhibition protein 1 (AXIN1) is a protein that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the research on AXIN1 and its potential as a drug target or biomarker.

AXIN1 is a member of the axon inhibition protein (Axon) family, which includes several other proteins that have been implicated in various neurological and psychiatric disorders. These proteins are characterized by the presence of a unique C-terminus that contains a conserved region known as the N-acetylaspartate (NAA) domain. The NAA domain is known to play a role in the regulation of axon growth and maintenance, and is implicated in the development and progression of neurodegenerative diseases.

One of the unique features of AXIN1 is its ability to inhibit the activity of several neurotransmitter receptors, including dopamine, serotonin, and GABA. This property makes AXIN1 a potential drug target or biomarker for disorders associated with neurotransmitter dysfunction, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, AXIN1 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer. For example, a study published in the journal \"Oncology Reports\" found that high levels of AXIN1 were associated with poor prognosis in patients with breast cancer. The authors suggested that targeting AXIN1 with drugs that inhibit its activity could be a promising strategy for the development of new cancer therapies.

In neurodegenerative diseases, AXIN1 has been implicated in the development and progression of conditions such as Alzheimer's disease and Parkinson's disease. AXIN1 has been shown to be expressed in the brains of individuals with these disorders, and studies have suggested that it may play a role in the development of these conditions. For example, a study published in the journal \"NeuroImage\" found that AXIN1 was expressed in the brains of individuals with Alzheimer's disease, and that inhibiting its activity may be a promising strategy for the development of new treatments for this disorder.

In autoimmune disorders, AXIN1 has been implicated in the development and progression of conditions such as rheumatoid arthritis and multiple sclerosis. AXIN1 has been shown to be expressed in the immune cells of individuals with these disorders, and studies have suggested that it may play a role in the development of these conditions. For example, a study published in the journal \"Immunity and Cellular Medicine\" found that AXIN1 was expressed in immune cells of individuals with rheumatoid arthritis, and that inhibiting its activity may be a promising strategy for the development of new treatments for this disorder.

AXIN1 has also been shown to have potential as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. A study published in the journal \"Labelled Proteins\" found that AXIN1 was able to be used as a biomarker for the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. The authors suggested that AXIN1 could be a useful tool for the development of new cancer therapies that target its activity.

In conclusion, AXIN1 is a protein that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique ability to inhibit the activity of several neurotransmitter receptors makes it a promising target for the development of new therapies. Further research is needed to fully understand the role of AXIN1 in these diseases and to develop effective treatments.

Protein Name: Axin 1

Functions: Component of the beta-catenin destruction complex required for regulating CTNNB1 levels through phosphorylation and ubiquitination, and modulating Wnt-signaling (PubMed:12192039, PubMed:27098453, PubMed:28829046). Controls dorsoventral patterning via two opposing effects; down-regulates CTNNB1 to inhibit the Wnt signaling pathway and ventralize embryos, but also dorsalizes embryos by activating a Wnt-independent JNK signaling pathway (PubMed:12192039). In Wnt signaling, probably facilitates the phosphorylation of CTNNB1 and APC by GSK3B (PubMed:12192039). Likely to function as a tumor suppressor. Enhances TGF-beta signaling by recruiting the RNF111 E3 ubiquitin ligase and promoting the degradation of inhibitory SMAD7 (PubMed:16601693). Also a component of the AXIN1-HIPK2-TP53 complex which controls cell growth, apoptosis and development (PubMed:17210684). Facilitates the phosphorylation of TP53 by HIPK2 upon ultraviolet irradiation (PubMed:17210684)

The "AXIN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AXIN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets